Table 3.
Relationship between US radiomics signature and LN metastasis in validation cohort after stratification.
| US radiomics signature | ||||
|---|---|---|---|---|
| Subgroup | LN metastasis (+) | LN metastasis (–) | P | |
| Gender | male | −0.225 (−0.354, −0.037) | −0.422 (−0.609, −0.226) | 0.003 |
| female | −0.229 (−0.323, −0.075) | −0.448 (−0.604, −0.280) | 0.000 | |
| US reported | LN+ | −0.228 (−0.354, −0.121) | −0.437 (−0.585, −0.283) | 0.000 |
| LN– | −0.228 (−0.328, −0.084) | −0.450 (−0.608, −0.302) | 0.000 | |
| Bethesda category | V | −0.229 (−0.322, −0.092) | −0.404 (−0.572, −0.294) | 0.000 |
| VI | −0.228 (−0.366, −0.129) | −0.442 (−0.602, −0.280) | 0.003 | |
| TSH | Abnormal (≥4.94 ng/ml) | −0.192 (−0.327, −0.081) | −0.411 (−0.664, −0.283) | 0.000 |
| normal (<4.94 ng/ml) | −0.228 (−0.334, −0.066) | −0.444 (−0.605, −0.279) | 0.003 | |
| TG | Abnormal (≥77 ng/ml) | −0.216 (−0.328, −0.084) | −0.351 (−0.529, −0.202) | 0.000 |
| normal (<77 ng/ml) | −0.459 (−0.610, −0.302) | −0.255 (−0.369, −0.111) | 0.000 | |
| TGAB | Abnormal (≥4.11 IU/ml) | −0.162 (−0.239, −0. 134) | −0.400 (−0.612, −0.218) | 0.000 |
| normal (<4.11 IU/ml) | −0.454 (−0.600, −0.309) | −0.264 (−0.350, −0.110) | 0.000 | |
| TPOAB | Abnormal (≥5.61 IU/ml) | 0.010 (−0.274, 0.148) | −0.315 (−0.512, −0.190) | 0.005 |
| normal (<5.61 IU/ml) | −0.459 (−0.609, −0.304) | −0.242 (−0.340, −0.094) | 0.000 | |
The score of US radiomics signature is expressed by median and quartile spacing.